688 reports of this reaction
5.6% of all ENFORTUMAB VEDOTIN reports
#3 most reported adverse reaction
NEUROPATHY PERIPHERAL is the #3 most commonly reported adverse reaction for ENFORTUMAB VEDOTIN, manufactured by SEAGEN INC.. There are 688 FDA adverse event reports linking ENFORTUMAB VEDOTIN to NEUROPATHY PERIPHERAL. This represents approximately 5.6% of all 12,251 adverse event reports for this drug.
Patients taking ENFORTUMAB VEDOTIN who experience neuropathy peripheral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROPATHY PERIPHERAL is moderately reported among ENFORTUMAB VEDOTIN users, representing a notable but not dominant share of adverse events.
In addition to neuropathy peripheral, the following adverse reactions have been reported for ENFORTUMAB VEDOTIN:
The following drugs have also been linked to neuropathy peripheral in FDA adverse event reports:
NEUROPATHY PERIPHERAL has been reported as an adverse event in 688 FDA reports for ENFORTUMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROPATHY PERIPHERAL accounts for approximately 5.6% of all adverse event reports for ENFORTUMAB VEDOTIN, making it one of the most commonly reported side effect.
If you experience neuropathy peripheral while taking ENFORTUMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.